Trials / Completed
CompletedNCT06735781
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
Short-term Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Nivolumab Plus Chemotherapy as Neoadjuvant Therapy in France
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 101 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate real-world effectiveness of neoadjuvant nivolumab plus chemotherapy in France.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | As prescribed by the treating clinician |
Timeline
- Start date
- 2024-09-05
- Primary completion
- 2024-10-01
- Completion
- 2024-10-01
- First posted
- 2024-12-16
- Last updated
- 2024-12-16
Locations
7 sites across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06735781. Inclusion in this directory is not an endorsement.